Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 22:35:43 UTC |
---|
Update Date | 2022-11-23 22:29:21 UTC |
---|
HMDB ID | HMDB0259747 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Valeryl 4-hydroxy valsartan |
---|
Description | 2-(1-hydroxypropan-2-yl)-3-oxo-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)heptanoic acid belongs to the class of organic compounds known as n-acyl-alpha amino acids. N-acyl-alpha amino acids are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. Based on a literature review very few articles have been published on 2-(1-hydroxypropan-2-yl)-3-oxo-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)heptanoic acid. This compound has been identified in human blood as reported by (PMID: 31557052 ). Valeryl 4-hydroxy valsartan is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Valeryl 4-hydroxy valsartan is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)C(C(C)CO)(C(O)=O)C(=O)CCCC InChI=1S/C29H37N5O5/c1-4-6-12-25(36)29(28(38)39,20(3)19-35)34(26(37)13-7-5-2)18-21-14-16-22(17-15-21)23-10-8-9-11-24(23)27-30-32-33-31-27/h8-11,14-17,20,35H,4-7,12-13,18-19H2,1-3H3,(H,38,39)(H,30,31,32,33) |
---|
Synonyms | Value | Source |
---|
2-(1-Hydroxypropan-2-yl)-3-oxo-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)heptanoate | Generator |
|
---|
Chemical Formula | C29H37N5O5 |
---|
Average Molecular Weight | 535.645 |
---|
Monoisotopic Molecular Weight | 535.279469311 |
---|
IUPAC Name | 2-(1-hydroxypropan-2-yl)-3-oxo-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)heptanoic acid |
---|
Traditional Name | 2-(1-hydroxypropan-2-yl)-3-oxo-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)heptanoic acid |
---|
CAS Registry Number | Not Available |
---|
SMILES | CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)C(C(C)CO)(C(O)=O)C(=O)CCCC |
---|
InChI Identifier | InChI=1S/C29H37N5O5/c1-4-6-12-25(36)29(28(38)39,20(3)19-35)34(26(37)13-7-5-2)18-21-14-16-22(17-15-21)23-10-8-9-11-24(23)27-30-32-33-31-27/h8-11,14-17,20,35H,4-7,12-13,18-19H2,1-3H3,(H,38,39)(H,30,31,32,33) |
---|
InChI Key | JXPAKNRYZWHNII-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as n-acyl-alpha amino acids. N-acyl-alpha amino acids are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | N-acyl-alpha amino acids |
---|
Alternative Parents | |
---|
Substituents | - Acyl-homoserine
- N-acyl-alpha-amino acid
- Biphenyl
- Phenyltetrazole
- Medium-chain keto acid
- Methyl-branched fatty acid
- Hydroxy fatty acid
- Heterocyclic fatty acid
- Branched fatty acid
- Beta-keto acid
- Amino fatty acid
- Fatty acyl
- Benzenoid
- N-acyl-amine
- Keto acid
- Beta-hydroxy ketone
- Monocyclic benzene moiety
- Heteroaromatic compound
- Tetrazole
- Tertiary carboxylic acid amide
- Azole
- Ketone
- Carboxamide group
- Azacycle
- Organoheterocyclic compound
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Carbonyl group
- Alcohol
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
valeryl 4-hydroxy valsartan,3TMS,isomer #1 | CCCC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)(C(C)CO[Si](C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1)C(=O)CCCC | 4095.3 | Semi standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #1 | CCCC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)(C(C)CO[Si](C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1)C(=O)CCCC | 3854.5 | Standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #1 | CCCC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)(C(C)CO[Si](C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1)C(=O)CCCC | 5195.7 | Standard polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #2 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(C(=O)CCCC)(C(=O)O[Si](C)(C)C)C(C)CO[Si](C)(C)C | 4191.0 | Semi standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #2 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(C(=O)CCCC)(C(=O)O[Si](C)(C)C)C(C)CO[Si](C)(C)C | 4056.5 | Standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #2 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(C(=O)CCCC)(C(=O)O[Si](C)(C)C)C(C)CO[Si](C)(C)C | 5092.6 | Standard polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #3 | CCCC=C(O[Si](C)(C)C)C(C(=O)O)(C(C)CO[Si](C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(=O)CCCC | 4264.0 | Semi standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #3 | CCCC=C(O[Si](C)(C)C)C(C(=O)O)(C(C)CO[Si](C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(=O)CCCC | 4003.1 | Standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #3 | CCCC=C(O[Si](C)(C)C)C(C(=O)O)(C(C)CO[Si](C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(=O)CCCC | 5301.3 | Standard polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #4 | CCCC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)(C(C)CO)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(=O)CCCC | 4218.3 | Semi standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #4 | CCCC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)(C(C)CO)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(=O)CCCC | 3981.7 | Standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TMS,isomer #4 | CCCC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)(C(C)CO)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(=O)CCCC | 5278.8 | Standard polar | 33892256 | valeryl 4-hydroxy valsartan,4TMS,isomer #1 | CCCC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)(C(C)CO[Si](C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(=O)CCCC | 4260.1 | Semi standard non polar | 33892256 | valeryl 4-hydroxy valsartan,4TMS,isomer #1 | CCCC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)(C(C)CO[Si](C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(=O)CCCC | 3973.6 | Standard non polar | 33892256 | valeryl 4-hydroxy valsartan,4TMS,isomer #1 | CCCC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)(C(C)CO[Si](C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)C(=O)CCCC | 4957.8 | Standard polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #1 | CCCC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)(C(C)CO[Si](C)(C)C(C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1)C(=O)CCCC | 4564.5 | Semi standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #1 | CCCC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)(C(C)CO[Si](C)(C)C(C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1)C(=O)CCCC | 4444.0 | Standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #1 | CCCC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)(C(C)CO[Si](C)(C)C(C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1)C(=O)CCCC | 5195.8 | Standard polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #2 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)C(C(=O)CCCC)(C(=O)O[Si](C)(C)C(C)(C)C)C(C)CO[Si](C)(C)C(C)(C)C | 4630.7 | Semi standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #2 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)C(C(=O)CCCC)(C(=O)O[Si](C)(C)C(C)(C)C)C(C)CO[Si](C)(C)C(C)(C)C | 4641.1 | Standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #2 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)C(C(=O)CCCC)(C(=O)O[Si](C)(C)C(C)(C)C)C(C)CO[Si](C)(C)C(C)(C)C | 5097.9 | Standard polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #3 | CCCC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O)(C(C)CO[Si](C)(C)C(C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)C(=O)CCCC | 4694.4 | Semi standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #3 | CCCC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O)(C(C)CO[Si](C)(C)C(C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)C(=O)CCCC | 4559.1 | Standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #3 | CCCC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O)(C(C)CO[Si](C)(C)C(C)(C)C)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)C(=O)CCCC | 5296.1 | Standard polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #4 | CCCC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)(C(C)CO)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)C(=O)CCCC | 4664.3 | Semi standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #4 | CCCC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)(C(C)CO)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)C(=O)CCCC | 4563.9 | Standard non polar | 33892256 | valeryl 4-hydroxy valsartan,3TBDMS,isomer #4 | CCCC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)(C(C)CO)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)C(=O)CCCC | 5277.2 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TBDMS_1_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TBDMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TBDMS_2_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TBDMS_2_5) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valeryl 4-hydroxy valsartan GC-MS (TBDMS_2_6) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum |
|
---|